Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a platform study of novel immunotherapy combinations in previously untreated advanced or metastatic non-small cell lung cancer
NL-OMON59134Phase 2Completed
- Sponsor
- GSK
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of dostarlimab in non-small cell lung cancer (NSCLC), sponsored by GSK. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 1 more. Started May 2023; status: completed.
02
Drugs
dostarlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59134.